What is he best known for?
The fields of study he is best known for:
- Antibody
- Virus
- Immune system
His primary scientific interests are in Virology, Antibody, Immunology, Neutralization and Epitope.
As a part of the same scientific study, Robert T. Bailer usually deals with the Virology, concentrating on Gp41 and frequently concerns with Viral entry and Protein structure.
He combines subjects such as Regimen and Immune system with his study of Antibody.
Robert T. Bailer interconnects Viral vector and HIV vaccine, Acquired immunodeficiency syndrome in the investigation of issues within Immunology.
His Neutralization study integrates concerns from other disciplines, such as Molecular biology, Potency and Binding site.
His Epitope research incorporates themes from Peptide sequence and Somatic hypermutation.
His most cited work include:
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial (1399 citations)
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody (631 citations)
- Structure and immune recognition of trimeric pre-fusion HIV-1 Env (544 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Virology, Antibody, Immunology, Epitope and Neutralization.
His specific area of interest is Virology, where Robert T. Bailer studies Virus.
In his research, Binding site, Protein structure and Mutation is intimately related to Glycan, which falls under the overarching field of Antibody.
His Immunology study typically links adjacent topics like HIV vaccine.
His Epitope research is multidisciplinary, incorporating elements of Lineage, Viral entry and B cell.
His research in Neutralization intersects with topics in Viral envelope, Glycoprotein, In vitro, Potency and Paratope.
He most often published in these fields:
- Virology (73.61%)
- Antibody (47.22%)
- Immunology (44.44%)
What were the highlights of his more recent work (between 2016-2021)?
- Antibody (47.22%)
- Virology (73.61%)
- Epitope (30.56%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Antibody, Virology, Epitope, Neutralization and Internal medicine.
His Antibody research includes elements of Immune system and Glycan.
His biological study spans a wide range of topics, including Immunogen, Immunization, Immunology and B cell.
Robert T. Bailer has included themes like HVTN 505 and Vector in his Immunology study.
As a part of the same scientific family, Robert T. Bailer mostly works in the field of Epitope, focusing on Lineage and, on occasion, Affinity maturation.
His Internal medicine research integrates issues from Reactogenicity and Vaccination.
Between 2016 and 2021, his most popular works were:
- Chimpanzee Adenovirus Vector Ebola Vaccine (168 citations)
- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials (149 citations)
- Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques (146 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Antibody
- Virus
Robert T. Bailer mostly deals with Antibody, Virology, Epitope, Virus and Monoclonal antibody.
His work on Neutralization is typically connected to Protein engineering as part of general Antibody study, connecting several disciplines of science.
His study looks at the relationship between Virology and fields such as Immunology, as well as how they intersect with chemical problems.
The Epitope study combines topics in areas such as Lineage, Somatic hypermutation, Neutralizing antibody and Affinity maturation.
His Virus study combines topics from a wide range of disciplines, such as In vitro, Potency, Hiv 1 envelope and Antigen.
In his study, Adverse effect and Clinical trial is strongly linked to myalgia, which falls under the umbrella field of Monoclonal antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
